SNX TD SYNNEX CORP Insider Trading

Director Richard T Hume sells 5,000 shares ($1.4M) at SNX under pre-arranged 10b5-1 plan

Richard T Hume, a director, executed 11 separate sales totaling 5,000 shares for $1,401,893.63 on 2026-06-02 under a 10b5-1 trading plan adopted on 2026-02-02, reducing his stake from 28,537 shares to 23,537 shares. This is a scheduled, non-discretionary transaction, so the sale timing reflects plan mechanics rather than director judgment. His prior trades at SNX show 30-day returns ranging from +20.4% to +22.6%, suggesting his past exit points at this ticker have historically been followed by continued stock appreciation. The current stock price of $279.25 sits -2.4% from the 52-week high of $286.25, while the 30-day and 90-day changes are +22.6% and +76.7% respectively, indicating the stock has rallied substantially in recent periods.

Director Richard T Hume executes 6 scheduled sales totaling 5,000 shares at SNX via 10b5-1 plan; retains 28,537 shares.

Richard T Hume sold 5,000 shares across 6 separate transactions on 2026-05-18, with prices ranging from $227.93 to $232.07 and a blended average of $229.54, for a total of $1,147,691.83. This sale reduces his holdings from 33,537 shares to 28,537 shares (-14.9% net change). The transaction is part of a pre-arranged 10b5-1 trading plan adopted 2026-02-02, meaning the sales were scheduled and not discretionary. At current price of $227.88, the stock trades -6.0% from its 52-week high of $242.49 and +6.3% over the past 30 days. Hume's prior sales at SNX (5 trades on 2026-05-05) showed modest negative 30-day and 90-day returns, though his cross-ticker track record showed average 90-day returns of +23.6% following prior sales, indicating mixed timing signals across his broader transaction history.

Director Richard T. Hume sells 5,000 SNX shares for $1.17M; repeat seller shows conflicting short- vs. long-term timing on prior trades.

Richard T. Hume, a director at TD SYNNEX, sold 5,000 shares on a single trading day for approximately $1.17 million, representing his tenth open-market sale at this company over the past three years. The stock is trading below its 52-week high but has rallied significantly over recent months on improving fundamentals—the company is profitable with growing revenue. Hume's five prior sales at SNX present a mixed timing picture: all five were well-timed at the 30-day horizon, meaning the stock did not rise further in the immediate aftermath, but all five proved poorly timed over the longer 90-day window as shares recovered and advanced substantially. This conflicting pattern—early timing that looked correct versus delayed outcomes that questioned the exit—repeats in his current sale. As a director with modest holdings, Hume continues a consistent pattern of open-market sales rather than purchases, adding to his track record of exits across his entire portfolio over the three-year filing window.

Director Saintil Merline sells majority stake worth ~$1M, trimming position as stock reaches near 52-week highs amid strong recent momentum.

Director Saintil Merline liquidated more than half of her holdings in a single transaction, offloading roughly one million dollars worth of TD SYNNEX stock. The timing is noteworthy: the stock is trading essentially at its 52-week high after a sharp run-up, having gained significantly over both the past month and quarter. This is classic opportunistic selling—a director taking advantage of a peak to diversify, rather than a panic exit during weakness. TD SYNNEX remains operationally healthy with profitable operations and strong revenue growth, so the sale doesn't signal fundamental distress. However, the decision to reduce exposure this substantially right at the peak, combined with the stock's already stretched valuation, suggests Merline saw a window to lock in gains and decided to take it.